The Food and Drug Administration (FDA) has approved Hyrimoz (adalimumab-adaz; Sandoz), a new biosimilar to Humira (adalimumab; AbbVie). Hyrimoz, a tumor necrosis factor (TNF)-blocker, is approved ...

In a phase 3 trial published in the British Journal of Dermatology, which included adults with clinically stable but active moderate-to-severe chronic plaque psoriasis, Hyrimoz and Humira showed a ...

The FDA has approved the third biosimilar to adalimumab, adalimumab-adaz, for all eligible indications of the biologic product, according to a company press release.Hyrimoz (adalimumab-adaz ...

Biosimilar Hyrimoz TM (adalimumab-adaz) approved for all indications of reference medicine not protected by orphan exclusivity ** Biosimilars are critical to sustaining US healthcare system ...

(RTTNews) - Sandoz said that the citrate-free high-concentration formulation or HCF of its biosimilar Hyrimoz (adalimumab-adaz) injection will be available in the United States starting July 1.

BOUCHERVILLE, Quebec, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sandoz Canada Inc. announced today the launch of Hyrimoz ® (adalimumab injection, reference biologic drug: Humira ®), which was authorized ...

(RTTNews) - Sandoz announced the European Medicines Agency has accepted the application for high concentration formulation 100 mg/mL of its biosimilar Hyrimoz for regulatory review. The company ...

Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference medicine Humira®*HCF formulation adalimumab offers ...